Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways

Cell Signal. 2006 Aug;18(8):1235-43. doi: 10.1016/j.cellsig.2005.10.005. Epub 2005 Nov 11.

Abstract

We recently reported that lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, stimulated inducible nitric oxide synthase (iNOS) expression, nitric oxide (NO) release, and cyclooxygenase-2 (COX-2) expression in RAW 264.7 macrophages. This study was carried out to further investigate the roles of COX-2 and prostaglandin E2 (PGE2) in LTA-induced iNOS expression and NO release in RAW 264.7 macrophages. Treatment of RAW 264.7 macrophages with LTA caused a time-dependent increase in PGE2 release. LTA-induced iNOS expression and NO release were inhibited by a non-selective COX inhibitor (indomethacin), a selective COX-2 inhibitor (NS-398), an adenylyl cyclase (AC) inhibitor (dideoxyadenosine, DDA), and a protein kinase A (PKA) inhibitor (KT-5720). Furthermore, both PGE2 and the direct PKA activator, dibutyryl-cAMP, also induced iNOS expression in a concentration-dependent manner. Stimulation of RAW 264.7 macrophages with LTA, PGE2, and dibutyryl-cAMP all caused p38 MAPK activation in a time-dependent manner. LTA-mediated p38 MAPK activation was inhibited by indomethacin, NS-398, and SB 203580, but not by PD 98059. The PGE2-mediated p38 MAPK activation was inhibited by DDA, KT-5720, and SB 203580, but not by PD 98059. LTA caused time-dependent activation of the nuclear factor-kappaB (NF-kappaB)-specific DNA-protein complex formation. The LTA-induced increase in kappaB-luciferase activity was inhibited by indomethacin, NS-398, KT-5720, and a dominant negative mutant of p38 alphaMAPK (p38 alphaMAPK DN). These results suggest that LTA-induced iNOS expression and NO release involve COX-2-generated PGE2 production, and AC, PKA, p38 MAPK, and NF-kappaB activation in RAW 264.7 macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Animals
  • Cells, Cultured
  • Cyclic AMP / pharmacology
  • Cyclic AMP-Dependent Protein Kinase Type II
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Cyclooxygenase 2 / metabolism*
  • Dinoprostone / biosynthesis
  • Dinoprostone / metabolism
  • Dinoprostone / pharmacology
  • Enzyme Activation / drug effects
  • Indomethacin / pharmacology
  • Kinetics
  • Lipopolysaccharides / pharmacology*
  • MAP Kinase Signaling System / drug effects
  • Macrophages / drug effects*
  • Macrophages / enzymology
  • Mice
  • Models, Biological
  • NF-kappa B / metabolism*
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism*
  • Nitrites / metabolism
  • Teichoic Acids / pharmacology*
  • Time Factors
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Lipopolysaccharides
  • NF-kappa B
  • Nitrites
  • Teichoic Acids
  • Nitric Oxide
  • lipoteichoic acid
  • Cyclic AMP
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • Cyclic AMP-Dependent Protein Kinase Type II
  • Cyclic AMP-Dependent Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Adenylyl Cyclases
  • Dinoprostone
  • Indomethacin